- Home
- CKPT vs SRG Comparison
CKPT vs SRG Comparison
Compare CKPT & SRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CKPT
- SRG
- Stock Information
- Founded
- CKPT 2014
- SRG 2014
- Country
- CKPT United States
- SRG United States
- Employees
- CKPT N/A
- SRG N/A
- Industry
- CKPT Biotechnology: Pharmaceutical Preparations
- SRG Real Estate Investment Trusts
- Sector
- CKPT Health Care
- SRG Real Estate
- Exchange
- CKPT Nasdaq
- SRG Nasdaq
- Market Cap
- CKPT 214.4M
- SRG 238.6M
- IPO Year
- CKPT 2017
- SRG 2015
- Fundamental
- Price
- CKPT $3.61
- SRG $4.09
- Analyst Decision
- CKPT Strong Buy
- SRG
- Analyst Count
- CKPT 3
- SRG 0
- Target Price
- CKPT $10.33
- SRG N/A
- AVG Volume (30 Days)
- CKPT 2.4M
- SRG 283.5K
- Earning Date
- CKPT 11-12-2024
- SRG 11-12-2024
- Dividend Yield
- CKPT N/A
- SRG N/A
- EPS Growth
- CKPT N/A
- SRG N/A
- EPS
- CKPT N/A
- SRG N/A
- Revenue
- CKPT $47,000.00
- SRG $56,359,000.00
- Revenue This Year
- CKPT N/A
- SRG N/A
- Revenue Next Year
- CKPT $151,162.55
- SRG N/A
- P/E Ratio
- CKPT N/A
- SRG N/A
- Revenue Growth
- CKPT N/A
- SRG N/A
- 52 Week Low
- CKPT $1.38
- SRG $3.63
- 52 Week High
- CKPT $4.50
- SRG $9.87
- Technical
- Relative Strength Index (RSI)
- CKPT 41.64
- SRG 40.43
- Support Level
- CKPT $2.98
- SRG $3.97
- Resistance Level
- CKPT $4.44
- SRG $4.55
- Average True Range (ATR)
- CKPT 0.42
- SRG 0.15
- MACD
- CKPT -0.10
- SRG -0.04
- Stochastic Oscillator
- CKPT 25.66
- SRG 19.31
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
About SRG Seritage Growth Properties
Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management and leasing of diversified and mixed-use properties throughout the United States.